Tilos Therapeutics
Developing innovative antibody therapeutics to target crucial immunological pathways with a focus on regulatory T cells and effector cell regulation.
Developing innovative antibody therapeutics to target crucial immunological pathways with a focus on regulatory T cells and effector cell regulation.
Tilos Therapeutics is a biotechnology and pharmaceutical startup that focuses on developing innovative antibody therapeutics targeting crucial immunological pathways, with a specific emphasis on regulatory T cells and effector cell regulation. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company's initial research is centered around antibodies specific to Latency Associated Peptide of TGF beta. In September 2017, Tilos Therapeutics secured a $3.05M Venture Round investment, with ShangPharma being the lead investor in this round.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $3.05M | 1 |
|
21 Sep 2017 |
| Seed Round | $750.00K | - | 30 Aug 2016 |
No recent news or press coverage available for Tilos Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
